{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:14:16Z","timestamp":1794006856895,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG 5184A2\/1"],"award-info":[{"award-number":["RG 5184A2\/1"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s13311-023-01402-3","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T14:02:22Z","timestamp":1689602542000},"page":"1263-1274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-4681","authenticated-orcid":false,"given":"Scott D.","family":"Newsome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn C.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra D.","family":"Cassard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Snoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.R.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Mowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1007\/s13311-023-01402-3_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0733-8619(18)30270-6","article-title":"Chronic nontraumatic diseases of the spinal cord","volume":"9","author":"Adams","year":"1991","journal-title":"Neurol Clin"},{"issue":"3","key":"10.1007\/s13311-023-01402-3_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/ana.410310317","article-title":"Revised estimate of the prevalence of multiple sclerosis in the United States","volume":"31","author":"Anderson","year":"1992","journal-title":"Ann Neurol"},{"issue":"2 Suppl","key":"10.1007\/s13311-023-01402-3_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458512441566","article-title":"Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries","volume":"18","author":"Karampampa","year":"2012","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-023-01402-3_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","article-title":"The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK","volume":"10","author":"Orme","year":"2007","journal-title":"Value Health"},{"key":"10.1007\/s13311-023-01402-3_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2010.02.008","article-title":"Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later","volume":"292","author":"Scott","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-023-01402-3_bib6","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.0b013e31823648b9","article-title":"Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis","volume":"77","author":"Sormani","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01402-3_bib7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1212\/01.wnl.0000342458.39625.91","article-title":"Demyelinating events in early multiple sclerosis have inherent severity and recovery","volume":"72","author":"Mowry","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-023-01402-3_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJMoa010994","article-title":"Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis","volume":"346","author":"Chang","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-023-01402-3_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/path.2582","article-title":"Enhanced number and activity of mitochondria in multiple sclerosis lesions","volume":"219","author":"Witte","year":"2009","journal-title":"J Pathol"},{"issue":"8","key":"10.1007\/s13311-023-01402-3_bib10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1177\/1352458512452924","article-title":"The role of mitochondria in axonal degeneration and tissue repair in MS","volume":"18","author":"van Horssen","year":"2012","journal-title":"Mult Scler"},{"issue":"52","key":"10.1007\/s13311-023-01402-3_bib11","doi-asserted-by":"crossref","first-page":"14189","DOI":"10.1523\/JNEUROSCI.4453-08.2008","article-title":"Recovery from chronic demyelination by thyroid hormone therapy; myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging","volume":"28","author":"Harsan","year":"2008","journal-title":"J Neurosci"},{"issue":"2","key":"10.1007\/s13311-023-01402-3_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-08-0573","article-title":"Age and stress as determinants of the severity of hyperthyroidism caused by Graves' disease in newly diagnosed patients","volume":"160","author":"Vos","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1007\/s13311-023-01402-3_bib13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/1352458509106212","article-title":"Assessing disability progression with the multiple sclerosis functional composite","volume":"15","author":"Rudick","year":"2009","journal-title":"Mult Scler"},{"issue":"1","key":"10.1007\/s13311-023-01402-3_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/WNL.47.1.129","article-title":"Validation of the functional assessment of multiple sclerosis quality of life instrument","volume":"47","author":"Cella","year":"1996","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01402-3_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102015","article-title":"Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: a dose-ranging study with assessment of reliability of visual outcomes","volume":"41","author":"Wooliscroft","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1007\/s13311-023-01402-3_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ncpendmet0590","article-title":"Potential therapeutic applications of thyroid hormone analogs","volume":"3","author":"Brenta","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"4","key":"10.1007\/s13311-023-01402-3_bib17","first-page":"462","article-title":"Molecular basis of thyroid hormone-dependent brain development","volume":"18","author":"Oppenheimer","year":"1997","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1007\/s13311-023-01402-3_bib18","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1210\/en.2007-1462","article-title":"Oxidative stress regulates type 3 deiodinase and type 2 deiodinase in cultured rat astrocytes","volume":"149","author":"Lamirand","year":"2008","journal-title":"Endocrinology"},{"issue":"1","key":"10.1007\/s13311-023-01402-3_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1677\/jme.0.0260067","article-title":"Thyroid hormone action in mitochondria","volume":"26","author":"Wrutniak-Cabello","year":"2001","journal-title":"J Mol Endocrinol"},{"issue":"2","key":"10.1007\/s13311-023-01402-3_bib20","doi-asserted-by":"crossref","first-page":"C355","DOI":"10.1152\/ajpcell.00415.2007","article-title":"Effect of thyroid hormone on mitochondrial properties and oxidative stress in cells from patients with mtDNA defects","volume":"296","author":"Menzies","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"10.1007\/s13311-023-01402-3_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/thy.2007.0250","article-title":"Thyroid hormone effects on mitochondrial energetics","volume":"18","author":"Harper","year":"2008","journal-title":"Thyroid"},{"issue":"8","key":"10.1007\/s13311-023-01402-3_bib22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/thy.2005.15.757","article-title":"Thyroid hormone transporters in health and disease","volume":"15","author":"Jansen","year":"2005","journal-title":"Thyroid"},{"issue":"3","key":"10.1007\/s13311-023-01402-3_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jad.2008.12.010","article-title":"The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS","volume":"116","author":"Kelly","year":"2009","journal-title":"J Affect Disord"},{"issue":"352","key":"10.1007\/s13311-023-01402-3_bib24","article-title":"Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE","volume":"15","author":"Chaudhary","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1007\/s13311-023-01402-3_bib25","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.expneurol.2008.04.039","article-title":"Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination","volume":"212","author":"Franco","year":"2008","journal-title":"Exp Neurol"},{"issue":"9","key":"10.1007\/s13311-023-01402-3_bib26","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1365-2826.2011.02181.x","article-title":"Triiodothyronine administration ameliorates the demyelination\/remyelination ratio in a non-human primate model of multiple sclerosis by correcting tissue hypothyroidism","volume":"23","author":"D'Intino","year":"2011","journal-title":"J Neuroendocrinol"},{"issue":"9","key":"10.1007\/s13311-023-01402-3_bib27","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/glia.22697","article-title":"A selective thyroid hormone \u03b2 receptor agonist enhances human and rodent oligodendrocyte differentiation","volume":"62","author":"Baxi","year":"2014","journal-title":"Glia"},{"issue":"3","key":"10.1007\/s13311-023-01402-3_bib28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00063030-200216030-00003","article-title":"Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials","volume":"16","author":"Wiendl","year":"2002","journal-title":"BioDrugs"},{"issue":"3","key":"10.1007\/s13311-023-01402-3_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10456-014-9418-5","article-title":"Modulation of angiogenesis by thyroid hormone and hormone analogues: implications for cancer management","volume":"17","author":"Mousa","year":"2014","journal-title":"Angiogenesis"},{"key":"10.1007\/s13311-023-01402-3_bib30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40478-014-0084-z","article-title":"Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"2","author":"Girolamo","year":"2014","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"10.1007\/s13311-023-01402-3_bib31","article-title":"Thyroid hormones interaction with immune response, inflammation and non-thyroidal illness syndrome","volume":"21","author":"De Luca","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1007\/s13311-023-01402-3_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102194","article-title":"Breaking the barriers to remyelination in multiple sclerosis","volume":"63","author":"Gharagozloo","year":"2022","journal-title":"Curr Opin Pharmacol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01402-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:12:35Z","timestamp":1761808355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923019256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1878747923019256"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01402-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01402-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}